Interleukins

DUPIXENT® (dupilumab injection) pre-filled pen now available in Canada, providing convenient self-administration option for people with type 2 inflammatory diseases

Retrieved on: 
Thursday, June 17, 2021

"Providing an option like the pre-filled pen for DUPIXENTmay offer patients a more convenient experience that may help ease the daily burden of treating their condition."

Key Points: 
  • "Providing an option like the pre-filled pen for DUPIXENTmay offer patients a more convenient experience that may help ease the daily burden of treating their condition."
  • The DUPIXENT pre-filled pen was designed to offer a more convenient and easy-to-use option for self-administration.
  • "Patient needs drive innovation at Sanofi, and insights from patients helped inform the development of the pre-filled pen for DUPIXENT.
  • DUPIXENT is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins and is not an immunosuppressant.

Protagonist Therapeutics Announces First Subject Dosed in Phase 1 Study of Oral IL-23 Receptor Antagonist PN-232

Retrieved on: 
Monday, May 24, 2021

NEWARK, Calif., May 24, 2021 /PRNewswire/ --Protagonist Therapeutics, Inc.(Nasdaq:PTGX) today announced that the first human subject has been dosed in a Phase 1 study of PN-232,a novel oral interleukin-23 receptor (IL-23R) antagonist peptide.

Key Points: 
  • NEWARK, Calif., May 24, 2021 /PRNewswire/ --Protagonist Therapeutics, Inc.(Nasdaq:PTGX) today announced that the first human subject has been dosed in a Phase 1 study of PN-232,a novel oral interleukin-23 receptor (IL-23R) antagonist peptide.
  • "PN-232 is a second-generation, oral, IL-23 receptor antagonist candidate currently being developed in collaboration with Janssen Research & Development, LLC," said Dinesh V. Patel, Ph.D., President and Chief Executive Officer at Protagonist.
  • PTG-200 is an orally delivered, gut-restricted, interleukin-23 receptor specific antagonist peptide in a Phase 2 clinical trial for Crohn's disease.
  • PN-235 and PN-232, both second-generation oral interleukin-23 receptor antagonist candidates, are in Phase 1 studies.

Xilio Therapeutics to Present Preclinical Data Highlighting Anti-Tumor Activity and Tolerability of XTX202 at the 2021 ASCO Annual Meeting

Retrieved on: 
Thursday, May 20, 2021

b'Xilio Therapeutics, a biotechnology company developing tumor-selective immuno-oncology therapies for patients with cancer, announced today the presentation of data from preclinical studies of XTX202, its tumor-selective interleukin-2 (IL-2) product candidate, demonstrating selective anti-tumor activity and favorable tolerability with no systemic toxicity observed.

Key Points: 
  • b'Xilio Therapeutics, a biotechnology company developing tumor-selective immuno-oncology therapies for patients with cancer, announced today the presentation of data from preclinical studies of XTX202, its tumor-selective interleukin-2 (IL-2) product candidate, demonstrating selective anti-tumor activity and favorable tolerability with no systemic toxicity observed.
  • The data will be reported in a poster entitled \xe2\x80\x9cXTX202, a protein-engineered IL-2, exhibits tumor-selective activity in mice without peripheral toxicities in non-human primates\xe2\x80\x9d at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • We are excited to present these data which, for the first time, demonstrate selective tumor-inhibition and favorable tolerability of XTX202 in preclinical models.
  • For more information, please visit www.xiliotx.com .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210520005158/en/\n'

NextCure to Present Trials in Progress Poster for NC410 at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Wednesday, May 19, 2021

\xe2\x80\x9cLAIR-1 expression on immune cells in the TME inhibits T cell responses, through binding to collagen therefore leading to tumor growth.

Key Points: 
  • \xe2\x80\x9cLAIR-1 expression on immune cells in the TME inhibits T cell responses, through binding to collagen therefore leading to tumor growth.
  • This leads to restoration of immune function as evidenced by increased production of several cytokines, and anti-tumor responses in preclinical models.
  • Because NC410 binds to collagen rich areas, it also induces alterations in the ECM to promote immune cell infiltration and function in the TME.
  • These statements are based on current expectations, forecasts, assumptions and other information available to NextCure as of the date hereof.

Connect Biopharma Announces First Patient Dosed in Phase 2 Trial Evaluating CBP-201 in Adults with Moderate-to-Severe Persistent Asthma

Retrieved on: 
Wednesday, May 12, 2021

Many patients with moderate-to-severe asthma continue to have unmet need and could benefit from additional treatment options,\xe2\x80\x9d said Zheng Wei, PhD, Co-founder and CEO of Connect Biopharma.

Key Points: 
  • Many patients with moderate-to-severe asthma continue to have unmet need and could benefit from additional treatment options,\xe2\x80\x9d said Zheng Wei, PhD, Co-founder and CEO of Connect Biopharma.
  • Type 2 inflammation is mediated by type 2 helper T-cells (TH2), which secrete inflammatory cytokines including IL-3, IL-4, L-5, IL-9 and IL-13.
  • The inclusion of forward-looking statements should not be regarded as a representation by Connect Biopharma that any of its plans will be achieved.
  • This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.\n'

Cantargia presents new preclinical data showing unique improvement of heart function in myocarditis using antibody CAN10

Retrieved on: 
Monday, May 10, 2021

These data demonstrate that the interleukin-1 receptor accessory protein (IL1RAP)-binding antibody CAN10 reduces inflammation and/or fibrosis in several disease models including myocarditis.

Key Points: 
  • These data demonstrate that the interleukin-1 receptor accessory protein (IL1RAP)-binding antibody CAN10 reduces inflammation and/or fibrosis in several disease models including myocarditis.
  • Favorable therapeutic effects were presented using a murine surrogate CAN10 antibody in multiple preclinical models of inflammatory or autoimmune diseases, including myocarditis.
  • In myocarditis, disease development is driven by inflammation and subsequent fibrosis of the myocardium, resulting in deterioration of the cardiac function.
  • CAN10 significantly reduced the development of inflammation and fibrosis in a preclinical model when treatment was given during five weeks after induction of disease.

Cue Biopharma to Present at the 2021 Frontiers in Cancer Immunotherapy Conference

Retrieved on: 
Thursday, May 6, 2021

b'CAMBRIDGE, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient\xe2\x80\x99s body, announced today it will give a poster presentation at the New York Academy of Sciences 2021 Frontiers in Cancer Immunotherapy meeting, which is being held virtually from May 12-14, 2021.

Key Points: 
  • b'CAMBRIDGE, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient\xe2\x80\x99s body, announced today it will give a poster presentation at the New York Academy of Sciences 2021 Frontiers in Cancer Immunotherapy meeting, which is being held virtually from May 12-14, 2021.
  • Quayle\xc2\xa0will discuss how the Immuno-STAT platform and biologics enable selective engagement of tumor-specific T cell repertoires against tumors.
  • He will showcase lead drug candidate, CUE-101, derived from the interleukin 2 (IL-2)-based CUE-100 series of Immuno-STATs that are designed for selective delivery of IL-2 to tumor-specific T cells.
  • The company\xe2\x80\x99s proprietary platform, Immuno-STAT\xe2\x84\xa2 (Selective Targeting and Alteration of T cells) is designed to harness the body\xe2\x80\x99s intrinsic immune system without the need for ex vivo manipulation.

MoonLake Immunotherapeutics announces publication in The Lancet of impressive Phase 2b data showing its Tri-specific Nanobody® Sonelokimab totally clears skin in almost 6 out of 10 patients with moderate to severe psoriasis

Retrieved on: 
Thursday, May 6, 2021

Sonelokimab is an investigational IL-17A/IL-17F inhibitor with an albumin binding site, which has the potential to facilitate deep tissue penetration in the skin and joints.

Key Points: 
  • Sonelokimab is an investigational IL-17A/IL-17F inhibitor with an albumin binding site, which has the potential to facilitate deep tissue penetration in the skin and joints.
  • In the highest dosage group, almost 6 out of 10 patients (57%) achieved total skin clearance (PASI 100 response) after 24 weeks.
  • Rapid response was demonstrated with one of three patients already achieving almost clear skin (PASI 90 response) by week 4.
  • Analysis of an individualized dosing scheme including off-drug periods in controlled patients revealed durable responses over one year.

MoonLake Immunotherapeutics announces publication in The Lancet of impressive Phase 2b data showing its Tri-specific Nanobody® Sonelokimab totally clears skin in almost 6 out of 10 patients with moderate to severe psoriasis

Retrieved on: 
Thursday, May 6, 2021

Sonelokimab is an investigational IL-17A/IL-17F inhibitor with an albumin binding site, which has the potential to facilitate deep tissue penetration in the skin and joints.

Key Points: 
  • Sonelokimab is an investigational IL-17A/IL-17F inhibitor with an albumin binding site, which has the potential to facilitate deep tissue penetration in the skin and joints.
  • In the highest dosage group, almost 6 out of 10 patients (57%) achieved total skin clearance (PASI 100 response) after 24 weeks.
  • Rapid response was demonstrated with one of three patients already achieving almost clear skin (PASI 90 response) by week 4.
  • Analysis of an individualized dosing scheme including off-drug periods in controlled patients revealed durable responses over one year.

Altavant Sciences Highlights Pipeline Progress in PAH and BOS at the International Society for Heart & Lung Transplantation Meeting

Retrieved on: 
Wednesday, April 21, 2021

Sustained exposure to the distal regions of the lungs is an important consideration for the efficacious treatment of BOS.

Key Points: 
  • Sustained exposure to the distal regions of the lungs is an important consideration for the efficacious treatment of BOS.
  • Further, treatment via a handheld nebulizer may provide a convenient portable intervention option for lung transplant patients experiencing BOS.
  • ALTA-2530, a recombinant human IL-1Ra, binds competitively to the IL-1 receptor to attenuate the inflammatory response.
  • ALTA-2530 is a recombinant human interleukin-1 receptor antagonist under development for bronchiolitis obliterans syndrome (BOS), a life-threatening form of chronic lung allograft dysfunction (CLAD) that frequently presents following lung transplantation.